Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen.
King CS, Flaherty KR, Glassberg MK, Lancaster L, Raghu G, Swigris JJ, Argula RG, Dudenhofer RA, Ettinger NA, Feldman J, Johri S, Fernandes P, Parsley E, Shah PS, Nathan SD. King CS, et al. Among authors: nathan sd. Ann Am Thorac Soc. 2022 Apr;19(4):594-602. doi: 10.1513/AnnalsATS.202107-864OC. Ann Am Thorac Soc. 2022. PMID: 34678128 Clinical Trial.
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators*. Raghu G, et al. Among authors: nathan sd. Ann Intern Med. 2013 May 7;158(9):641-9. doi: 10.7326/0003-4819-158-9-201305070-00003. Ann Intern Med. 2013. PMID: 23648946 Clinical Trial.
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.
Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group. Saketkoo LA, et al. Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Thorax. 2014. PMID: 24368713 Free PMC article.
Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.
Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Saketkoo LA, et al. J Rheumatol. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. J Rheumatol. 2014. PMID: 24488412 Free PMC article. Review.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. King TE Jr, et al. Among authors: nathan sd. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Free article. Clinical Trial.
286 results